Thymosin Beta 4 Promotes Dermal Healing

The document from January 1, 2016, detailed the beneficial effects of Thymosin β4 (Tβ4) in promoting dermal healing. Tβ4, a regenerative protein, was found to have angiogenic and anti-inflammatory properties and played a significant role in wound healing by reducing inflammation, promoting cell migration, angiogenesis, and stem cell recruitment. It was shown to improve healing rates in various animal models, including those with diabetes and aging, and in human clinical trials involving patients with pressure ulcers, venous stasis ulcers, and epidermolysis bullosa wounds. The trials, which included a phase 1 safety trial with 15 volunteers and phase 2 trials with a total of 172 patients, indicated that Tβ4 was safe and well-tolerated, with a trend toward faster healing at certain concentrations. The document concluded that Tβ4 has potential as a therapeutic agent for enhancing dermal healing and reducing scarring, and that more clinical studies are needed to define its efficacy and optimal dosing.